McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada.
Infect Dis Ther. 2013 Dec;2(2):83-93. doi: 10.1007/s40121-013-0020-8. Epub 2013 Nov 19.
HIV drug resistance has been one of the major obstacles to HIV eradication and has contributed to the need for the constant development of new antiretroviral drugs over the past 25 years. With the recent approval of dolutegravir for human therapy by the U.S. Food and Drug Administration, health practitioners may soon have access to three integrase strand transfer inhibitors to treat individuals living with HIV. Here, we review the use of raltegravir, elvitegravir, and dolutegravir for use in first- and second-line HIV treatment regimens and the issue of HIV resistance against integrase inhibitors.
HIV 耐药性一直是 HIV 根除的主要障碍之一，也是过去 25 年来不断开发新的抗逆转录病毒药物的原因。随着美国食品和药物管理局最近批准多替拉韦用于人体治疗，医疗保健从业者可能很快将有三种整合酶链转移抑制剂可用于治疗 HIV 感染者。在这里，我们回顾了雷替拉韦、艾维雷韦和多替拉韦在一线和二线 HIV 治疗方案中的应用，以及针对整合酶抑制剂的 HIV 耐药性问题。
